Канада - Енглески - Health Canada

apotex inc - methylphenidate hydrochloride - tablet - 10mg - methylphenidate hydrochloride 10mg - respiratory and cns stimulants

Канада - Енглески - Health Canada

apotex inc - methylphenidate hydrochloride - tablet - 20mg - methylphenidate hydrochloride 20mg - respiratory and cns stimulants

Канада - Енглески - Health Canada

apotex inc - methylphenidate hydrochloride - tablet (extended-release) - 20mg - methylphenidate hydrochloride 20mg - respiratory and cns stimulants

Канада - Енглески - Health Canada

apotex inc - methylphenidate hydrochloride - tablet - 5mg - methylphenidate hydrochloride 5mg - respiratory and cns stimulants

Канада - Енглески - Health Canada

pharmascience inc - methylphenidate hydrochloride - tablet - 10mg - methylphenidate hydrochloride 10mg - respiratory and cns stimulants

Канада - Енглески - Health Canada

pharmascience inc - methylphenidate hydrochloride - tablet - 20mg - methylphenidate hydrochloride 20mg - respiratory and cns stimulants

Канада - Енглески - Health Canada

pharmascience inc - methylphenidate hydrochloride - tablet - 5mg - methylphenidate hydrochloride 5mg - respiratory and cns stimulants

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

avera mckennan hospital - dexmethylphenidate hydrochloride (unii: 1678ok0e08) (dexmethylphenidate - unii:m32rh9mfgp) - dexmethylphenidate hydrochloride 20 mg - dexmethylphenidate hydrochloride extended-release capsules are indicated for the treatment of attention deficit hyperactivity disorder (adhd) in patients aged 6 years and older. the effectiveness of dexmethylphenidate hydrochloride extended-release capsules in the treatment of adhd in patients aged 6 years and older was established in 2 placebo-controlled studies in patients meeting dsm-iv criteria for adhd [see clinical studies (14) ]. a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of atten

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 20 mg - methylphenidate hydrochloride extended-release capsules are indicated for the treatment of attention deficit hyperactivity disorder (adhd), in pediatric patients 6 to 12 years of age [see clinical studies (14)] . - hypersensitivity to methylphenidate or other components of methylphenidate hydrochloride extended-release capsules. hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with methylphenidate [ s ee adverse reactions (6.1)]. - concomitant treatment with monoamine oxidase inhibitors (maois), or within 14 days following discontinuation of treatment with an maoi, because of the risk of hypertensive crises [ see drug interactions (7.1)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to adhd medications, including methylphenidate hydrochloride extended-release capsules during pregnancy. healthcare providers are encouraged to register patients by calling the national pregna

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

novel laboratories, inc. - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 5 mg - attention deficit disorders, narcolepsy attention deficit disorders  (previously known as minimal brain dysfunction in children). other terms being used to describe the behavioral syndrome below include: hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction. methylphenidate hydrochloride is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous system dysfun